

540, 099

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 July 2004 (08.07.2004)

PCT

(10) International Publication Number
WO 2004/056389 A1

- (51) International Patent Classification⁷: **A61K 39/12**
- (21) International Application Number: **PCT/EP2003/014562**
- (22) International Filing Date:
18 December 2003 (18.12.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/435,035 20 December 2002 (20.12.2002) US
60/496,653 20 August 2003 (20.08.2003) US
- (71) Applicant (for all designated States except US): **GLAXOSMITHKLINE BIOLOGICALS SA [BE/BE]**; Rue de l'Institut 89, B-1330 Rixensart (BE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **DUBIN, Gary** [US/US]; GlaxoSmithKline, 2301 Renaissance Blvd. RN0220, Bldg. 510, P.O. Box 61540, King of Prussia, PA 19406-2772 (US). **INNIS, Bruce** [US/US]; GlaxoSmithKline, 2301 Renaissance Blvd. RN0220, Bldg. 510, P.O. Box 61540, King of Prussia, PA 19406-2772 (US). **SLAOUL, Moncef, Mohammed** [BE/BE]; GlaxoSmithKline Biologicals SA, rue de l'Institut 89, B-1330 Rixensart (BE). **WETTENDORFF, Martine, Anne,**
- Cecile [BE/BE]; GlaxoSmithKline Biologicals SA, rue de l'Institut 89, B-1330 Rixensart (BE).
- (74) Agents: **STEPHEN, Robert, J. et al.**; GlaxoSmithKline, CIP (CN925.1), 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- with international search report
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: HPV-16 AND -18 L1 VLP VACCINE

(57) Abstract: The invention relates to use of HPV 16 and HPV 18 VLPs to provide cross protection against infection and/or disease by other HPV types.

WO 2004/056389 A1